News NIH abandons trial of SIGA's mpox drug Another clinical trial has found that SIGA Technologies' antiviral drug TPOXX (tecovirimat) is ineffective as a treatment for mpox.
News Lynparza boosts long-term survival in early breast cancer A single year of adjuvant treatment with AstraZeneca and MSD's PARP inhibitor Lynparza is still providing a survival benefit six years later.
News Mulvany hits the reset button at BenevolentAI The shape of BenevolentAI following the return of co-founder Ken Mulvany has started to crystallise and could see the company return to private hands.
News Refiling for cALD therapy on the cards after new data Readout from NEXUS study sets up mid-2025 refiling for Minoryx and Neuraxpharm's leriglitazone for rare disease cerebral adrenoleukodystrophy (cALD).
News Drug-digital dual therapy for depression starts phase 2 Gate Neurosciences' antidepressant apimostinel has started a proof-of-concept study to see if its efficacy can be boosted by a digital training tool.
News uniQure rockets on map to market for Huntington's therapy uniQure says it has reached agreement with the FDA on a pathway to accelerated approval for its much-anticipated Huntington's disease gene therapy.
Patients On addressing drug waste and ensuring access, with Jeff Harp... The rising cost of drugs in 2025 was driven by several factors, including inflation, supply chain issues, and the demand for specialty drugs.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
